Cargando…

Dual-Tracer PET-MRI-Derived Imaging Biomarkers for Prediction of Clinically Significant Prostate Cancer

Purpose: To investigate if imaging biomarkers derived from 3-Tesla dual-tracer [(18)F]fluoromethylcholine (FMC) and [(68)Ga]Ga-PSMA(HBED-CC) conjugate 11 (PSMA)-positron emission tomography can adequately predict clinically significant prostate cancer (csPC). Methods: We assessed 77 biopsy-proven PC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grubmüller, Bernhard, Huebner, Nicolai A., Rasul, Sazan, Clauser, Paola, Pötsch, Nina, Grubmüller, Karl Hermann, Hacker, Marcus, Hartenbach, Sabrina, Shariat, Shahrokh F., Hartenbach, Markus, Baltzer, Pascal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954891/ https://www.ncbi.nlm.nih.gov/pubmed/36826090 http://dx.doi.org/10.3390/curroncol30020129

Ejemplares similares

Feasibility and Optimal Time Point of [(68)Ga]Gallium-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography Imaging in Patients Undergoing Cytoreductive Surgery After Systemic Therapy for Primary Oligometastatic Prostate Cancer: Implications for Patient Selection and Extent of Surgery
por: Huebner, Nicolai, et al.
Publicado: (2022)

Response assessment using (68)Ga-PSMA ligand PET in patients undergoing (177)Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer
por: Grubmüller, Bernhard, et al.
Publicado: (2018)

Clinical outcome of standardized (177)Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks
por: Rasul, Sazan, et al.
Publicado: (2019)

Prospective evaluation of the performance of [(68)Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy
por: Abufaraj, Mohammad, et al.
Publicado: (2019)

Prediction of response and survival after standardized treatment with 7400 MBq (177)Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer
por: Rasul, Sazan, et al.
Publicado: (2020)

[(18)F]DOPA PET/ceCT in diagnosis and staging of primary medullary thyroid carcinoma prior to surgery
por: Rasul, Sazan, et al.
Publicado: (2018)

Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Wollenweber, Tim, et al.
Publicado: (2021)

Prospective validation of 18F-Fluoroethylcholine as a tracer in PET/MRI for the evaluation of breast lesions and prediction of lymph node status
por: Clauser, Paola, et al.
Publicado: (2023)

Visibility of significant prostate cancer on multiparametric magnetic resonance imaging (MRI)—do we still need contrast media?
por: Huebner, Nicolai Alexander, et al.
Publicado: (2020)

(68)Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy – diagnostic performance and impact on therapeutic decision-making
por: Grubmüller, B., et al.
Publicado: (2017)

Supervised machine learning enables non-invasive lesion characterization in primary prostate cancer with [(68)Ga]Ga-PSMA-11 PET/MRI
por: Papp, L., et al.
Publicado: (2020)

A Simultaneous Multiparametric (18)F-FDG PET/MRI Radiomics Model for the Diagnosis of Triple Negative Breast Cancer
por: Romeo, Valeria, et al.
Publicado: (2022)

Quantitative assessment of atherosclerotic plaques on (18)F-FDG PET/MRI: comparison with a PET/CT hybrid system
por: Li, Xiang, et al.
Publicado: (2016)

Erratum to: Quantitative assessment of atherosclerotic plaques on (18)F-FDG PET/MRI: comparison with a PET/CT hybrid system
por: Li, Xiang, et al.
Publicado: (2016)

Response and Toxicity to the Second Course of 3 Cycles of (177)Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Rasul, Sazan, et al.
Publicado: (2021)

Response to [(177)Lu]Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients presenting with only lymph node metastases
por: Zisser, Lucia, et al.
Publicado: (2022)

Assessment of left and right ventricular functional parameters using dynamic dual-tracer [(13)N]NH3 and [(18)F]FDG PET/MRI
por: Rasul, Sazan, et al.
Publicado: (2020)

Simultaneous 18F-FDG PET/MRI Radiomics and Machine Learning Analysis of the Primary Breast Tumor for the Preoperative Prediction of Axillary Lymph Node Status in Breast Cancer
por: Romeo, Valeria, et al.
Publicado: (2023)

Response evaluation of SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus using (18)F-FDG PET/MRI
por: Rasul, Sazan, et al.
Publicado: (2020)

Analysis of hematological parameters as prognostic markers for toxicity and survival of (223)Radium treatment
por: Leisser, Asha, et al.
Publicado: (2018)

Direct Patlak Reconstruction of [(68)Ga]Ga-PSMA PET for the Evaluation of Primary Prostate Cancer Prior Total Prostatectomy: Results of a Pilot Study
por: Rasul, Sazan, et al.
Publicado: (2023)

Assessing the kidney function parameters glomerular filtration rate and effective renal plasma flow with dynamic FDG-PET/MRI in healthy subjects
por: Geist, Barbara K., et al.
Publicado: (2018)

Assessment of the kidney function parameters split function, mean transit time, and outflow efficiency using dynamic FDG-PET/MRI in healthy subjects
por: Geist, Barbara K., et al.
Publicado: (2019)

Assessment of attenuation correction for myocardial PET imaging using combined PET/MRI
por: Lassen, Martin Lyngby, et al.
Publicado: (2017)

Dynamic 2-deoxy-2[18F] fluoro-D-glucose PET/MRI in human renal allotransplant patients undergoing acute kidney injury
por: Pajenda, Sahra, et al.
Publicado: (2020)

Can supplementary contrast-enhanced MRI of the breast avoid needle biopsies in suspicious microcalcifications seen on mammography? A systematic review and meta-analysis
por: Fueger, Barbara J., et al.
Publicado: (2021)

AI-enhanced simultaneous multiparametric (18)F-FDG PET/MRI for accurate breast cancer diagnosis
por: Romeo, V., et al.
Publicado: (2021)

Evaluation of the Predictive Role of Blood-Based Biomarkers in the Context of Suspicious Prostate MRI in Patients Undergoing Prostate Biopsy
por: Rajwa, Pawel, et al.
Publicado: (2021)

Uncertainties in Markov State Models of Small Proteins
por: Kozlowski, Nicolai, et al.
Publicado: (2023)

Impact of ECG gating methods on the assessment of left ventricular cardiac function using PET/MRI
por: Rasul, Sazan, et al.
Publicado: (2022)

Update on PET Tracer Development for Muscarinic Acetylcholine Receptors
por: Ozenil, Marius, et al.
Publicado: (2021)

An A.I. classifier derived from 4D radiomics of dynamic contrast-enhanced breast MRI data: potential to avoid unnecessary breast biopsies
por: Pötsch, Nina, et al.
Publicado: (2021)

Attenuation Correction Approaches for Serotonin Transporter Quantification With PET/MRI
por: Rischka, Lucas, et al.
Publicado: (2019)

Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [(68)Ga]Ga-Pentixafor-PET/MRI
por: Haug, Alexander R., et al.
Publicado: (2019)

Salvage Radical Prostatectomy for Radio-Recurrent Prostate Cancer: An Updated Systematic Review of Oncologic, Histopathologic and Functional Outcomes and Predictors of Good Response
por: Grubmüller, Bernhard, et al.
Publicado: (2021)

Breast MRI: does a clinical decision algorithm outweigh reader experience?
por: Pötsch, Nina, et al.
Publicado: (2022)

Comparative effectiveness of moderate hypofractionation with volumetric modulated arc therapy versus conventional 3D-radiotherapy after radical prostatectomy
por: Moll, Matthias, et al.
Publicado: (2022)

3D T2-weighted imaging to shorten multiparametric prostate MRI protocols
por: Polanec, Stephan H., et al.
Publicado: (2017)

Scheelite-type sodium neodymium(III) ortho-oxidomolybdate(VI), NaNd[MoO(4)](2)
por: Schleid, Thomas, et al.
Publicado: (2011)

Accuracy of PET quantification in [(68)Ga]Ga-pentixafor PET/MR imaging of carotid plaques
por: Rausch, Ivo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jhra9pcbc8l9n96m2oeup7cmd9